Inotek Pharmaceuticals – $50 Million Follow-On

New York – August 18, 2016 – Cooley advised the underwriters on Inotek Pharmaceuticals' $50 million offering of 5.75% convertible senior notes due 2021.

Inotek, which trades on The NASDAQ Global Market, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.

Cowen & Company and Piper Jaffray acted as joint book-running managers for the offering. J. Wood Capital Advisors and Perella Weinberg Partners acted as financial advisors to the company.

Cooley advised the underwriters on Inotek's IPO and concurrent convertible senior notes offering in February 2015, as well as the company's follow-on offering in August 2015 and its at-the-market equity offering in April 2016.

The Cooley securities and debt team advising the underwriters included Div Gupta, Mischi a Marca, Josh Kaufman, Jason Savich, Jonie Kondracki, Pia Kaur and Michael Schaeppi.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Div Gupta Partner, New York
Mischi a Marca Partner, San Francisco
Josh Kaufman Partner, New York
Wendy Goldstein Partner, New York
Natasha Leskovsek Partner, Washington, DC
Matthew Pavao Partner, Boston
Susan Cooper Philpot Retired Partner, San Francisco
Phil Mitchell Partner, New York
Jason Savich Partner, San Francisco
Jonie Kondracki Partner, San Francisco
Pia Kaur Associate, New York